Tetra Radar · FDA Approvals · Decision date

neladalkib: FDA decision date

Gsk PLC (GSK) · November 2026

Neladalkib is an investigational ALK tyrosine kinase inhibitor (TKI) currently under review with the US FDA for use by patients with TKI pre-treated ALK-positive NSCLC, with PDUFA date anticipated in November 2026.

Source: 6-K of 8 September 2026

The decision is pending.

Gsk PLC on Tetra Radar

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.